MedPath

Role of Laghumanjisthadi Ghana and Raktamokshan in Gout.

Phase 3
Conditions
Health Condition 1: M958- Other specified acquired deformities of musculoskeletal system
Registration Number
CTRI/2024/08/071793
Lead Sponsor
Dr Pranoti Tukaram Khandekar
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients having clinical signs and symptoms of vatrakta with special reference to gout like Sandhi toda(jiont pricking pain),Sandhi daha(burning sensation),Sparshasahatva(Tenderness),Sandhi shotha (swelling),Raga (redness or discolouration of joint)described in aaaaaaaaayurvedic classics without any bar of caste ,sex,religion .

2 Patient having serum uric acid level above 6

Exclusion Criteria

1 Patients having chronicity of vatrakta more than 5 years

2 Patients on Anti platelet aggregation drugs

3 Patients on anti coagulant drugs

4 Patients having bleeding disorders

5 Patients contraindicated for for Raktamokshana

6 Pregnant and Lactating mothers

7 Patients with illness like HIV, Malignancy,Cardiac disease ,Major Liver Disorders ,Uncontrolled Hypertension , End stage Renal disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To Evaluate the efficacy Hypourecemic effect of Laghumanjisthadi Ghana and Raktamokshan in the management of Vatarakta.Timepoint: 21 days
Secondary Outcome Measures
NameTimeMethod
1 To evaluate the Hypourecemic effect of Laghumanjisthadi Ghana & Raktamokshan in Vatarakta. <br/ ><br>2.To study adverse effect of Laghumanjisthadi Ghana if any <br/ ><br> 3 To study adverse effect of Raktamokshan if any <br/ ><br>4.To study etiopathology of Vatarakta.Timepoint: 21 days
© Copyright 2025. All Rights Reserved by MedPath